OnconetixONCO -11.53%23 Days Payable is 6,528.34 as of Mar. 2026, which is 479% above its 10-year median of 1,128.42. GuruFocus rates ONCO with a GF Score™ of 23/100. The stock has 4 warning signs investors should review. Among 702 Biotechnology companies, Onconetix ranks better than 94.02% on this metric.
Onconetix's average Accounts Payable for the
three
months ended in Mar. 2026 was $1.65 Mil. Onconetix's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $0.02 Mil.
Hence, Onconetix's Days Payable for the
three
months ended in Mar. 2026 was 6,528.34.
The historical rank and industry rank for Onconetix's Days Payable or its related term are showing as below:
ONCO'
s Days Payable Range Over the Past 10 Years
Min: 1046.33 Med: 1128.42 Max: 5561.24
Current: 5026.22
During the past 7 years, Onconetix's highest Days Payable was 5561.24. The lowest was 1046.33. And the median was 1128.42.
ONCO's Days Payable is ranked better than 94.02% of 702
companies
in the Biotechnology industry
Industry Median: 113.56
vs ONCO: 5026.22
Onconetix's Days Payable
increased
from Mar. 2025 (5,189.84) to Mar. 2026 (6,528.34).
It may suggest that Onconetixdelayed paying its suppliers.
Onconetix Days Payable Related Terms
Onconetix Days Payable Historical Data
* Premium members only.
The historical data trend for Onconetix's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Onconetix's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Onconetix Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Onconetix's Days Payable distribution charts can be found below:
* The bar in red indicates where Onconetix's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Onconetix's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Onconetix (ONCO) has a Days Payable of 6,528.34 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Onconetix and its competitors. This is 479% above median its historical median of 1,128.42. Over the past decade, Onconetix's Days Payable has ranged from 1,046.33 to 5,561.24. According to the industry distribution chart, Onconetix ranks #42 out of 702 companies in the Biotechnology industry, placing it in the top 6%.
Is Onconetix's Days Payable too high?
Onconetix's current Days Payable of 6,528.34 is 479% above median its 10-year median of 1,128.42. Over the past 10 years, this metric has ranged from a low of 1,046.33 to a high of 5,561.24. The Biotechnology industry median Days Payable is 113.56. Onconetix's value of 6,528.34 is 5648.8% above this industry median. Based on the distribution chart, Onconetix ranks #42 out of 702 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Onconetix has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Onconetix's Days Payable compare to CMND and REVB?
According to the Biotechnology industry distribution chart, Onconetix ranks #42 out of 702 companies for Days Payable. This places Onconetix in the top 6% of its industry — outperforming the majority of peers. The industry median Days Payable is 113.56. Onconetix's value of 6,528.34 is 5648.8% above this benchmark. Historically, Onconetix's own Days Payable has ranged from 1,046.33 to 5,561.24 over the past decade. While the company's 10-year median is 1,128.42 vs. the industry median of 113.56, Onconetix has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Onconetix's current Days Payable of 6,528.34 is 5648.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Onconetix and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Onconetix's current Days Payable is 6,528.34, which is 479% above median its own 10-year median of 1,128.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Onconetix stock overvalued right now?
Onconetix (ONCO) has a current Days Payable of 6,528.34. The current Days Payable is 6,528.34, which is 479% above median its 10-year median of 1,128.42 and 5648.8% above the Biotechnology industry median of 113.56. Onconetix's overall GF Score™ is 23/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Onconetix (ONCO), the current Days Payable is 6,528.34 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.
23GF Score
Get the complete analysis for ONCO
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ONCO has been successfully added to your 
